Haemonetics Corporation (HAE)

Market Cap	2.68B -23.1%
Revenue (ttm)	1.32B -4.0%
Net Income	175.44M +34.9%
EPS	3.65 +43.8%
Shares Out	46.47M
PE Ratio	15.82
Forward PE	11.18
Dividend	n/a
Ex-Dividend Date	n/a

Volume	671,446
Open	57.70
Previous Close	57.64
Day's Range	57.44 - 59.33
52-Week Range	47.32 - 87.32
Beta	0.27
Analysts	Buy
Price Target	86.00 (+48.89%)
Earnings Date	Feb 5, 2026

About HAE

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools....

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: May 9, 1991
• Employees: 3,023
• Stock Exchange: NYSE
• Ticker Symbol: HAE
• Website: https://www.haemonetics.com

Financial Performance

In fiscal year 2025, Haemonetics's revenue was $1.36 billion, an increase of 3.95% compared to the previous year's $1.31 billion. Earnings were $167.68 million, an increase of 42.64%.

Analyst Summary

According to 9 analysts, the average rating for HAE stock is "Buy." The 12-month stock price target is $86.0, which is an increase of 48.89% from the latest price.

Price Target

$86.0

(48.89% upside)

Analyst Consensus: Buy